[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

World Market for Prescription Arthritis Treatments

21 Dec 2011 • by Natalie Aster

One of the biggest problems facing insurance reimbursement of rheumatoid arthritis is the growing use of biologics as a primary treatment method. Biopharmaceuticals are most commonly defined as drugs that are produced through biological processes that structurally mimic compounds within the body. These include recombinant proteins, monoclonal and polyclonal antibodies, peptides, antisense oligonucleotides, and therapeutic genes —all requiring far more complex administration, distribution, and reimbursement methodologies than conventional oral medications.

According to the report "World Market for Prescription Arthritis Treatments" by Kalorama Informationl Ltd most biologics fall into the category of specialty pharmaceuticals, which are premium-priced infused or injected drugs that require special handling and are indicated primarily for long-term and/or life-threatening diseases. Typically, there is a high unmet need for specialty pharmaceuticals.

Report Details:

World Market for Prescription Arthritis Treatments
Published: November 2011
Pages: 150
Price: US$ 3,500.00

As payers struggle to realign their policies and procedures to accommodate the influx of these expensive high-tech drugs, health plans are increasingly turning to specialty pharmacy providers to manage the acquisition.

More information can be found in the report “World Market for Prescription Arthritis Treatments” by Kalorama Information.

To order the report or ask for sample pages contact [email protected]


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest